Status:
COMPLETED
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Lead Sponsor:
Aprea Therapeutics
Conditions:
Hematologic Neoplasms
Prostatic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.
Eligibility Criteria
Inclusion
- Summary criteria for participant selection:
- Inclusion Criteria:
- Male or female ≥ 18 years of age.
- Any below mentioned advanced disease, which is not eligible for other therapies. The diagnosis should have been confirmed either histologically or cytologically:
- Acute myeloid leukemia.
- Acute lymphoid leukemia.
- Chronic lymphocytic leukemia.
- Chronic myeloid leukemia.
- Chronic myelomonocytic leukemia.
- Multiple myeloma.
- Non Hodgkin's lymphoma.
- Hodgkin's lymphoma.
- Myelodysplastic syndrome.
- Myelofibrosis.
- Hormone refractory, metastatic prostate carcinoma.
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00900614
Start Date
May 1 2009
End Date
October 1 2010
Last Update
July 31 2019
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Section of Haematology and Coagulation, Sahlgrenska University Hospital
Gothenburg, Sweden, 41345
2
Department of Hematology, University Hospital
Örebro, Sweden, 70185
3
Urology clinic, University Hospital
Örebro, Sweden, 70185
4
Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge
Stockholm, Sweden, SE 141 86